The State of Multiple Sclerosis Therapy and Trends in Thinking: Robert K. Shin, MD
May 30th 2022The professor of neurology at MedStar Georgetown University Hospital shared his perspective on the trends in thinking about the treatment of MS and how an improved understanding of underlying processes has led to a shift in the field. [WATCH TIME: 5 minutes]
The Benefits of Mobile Stroke Units: Alvin Wang, DO, BC-EMS
May 27th 2022The chief of emergency medical services at Jefferson Health spoke about the operation of the Jefferson mobile stroke unit in the field, and the impact that the onset of the COVID-19 pandemic had on launching the program. [WATCH TIME: 3 minutes]
Optimizing Mobile Stroke Units and Dealing With Associated Costs: Gregory W. Albers, MD
May 26th 2022The director of the Stanford Stroke Center and Coyote Foundation Professor of Neurology and Neurological Sciences at Stanford Medical Center shared his perspective on the uptake of mobile stroke units across the United States. [WATCH TIME: 6 minutes]
Progress in Neurogenerative Disease Drug Development: Gregory A. Rippon, MD, MS
May 19th 2022The chief medical partner of neurology, ophthalmology, and internal medicine at Genentech shared his perspective on the steps the field has taken to improve clinical trials and therapies for neurodegenerative diseases such as Alzheimer disease. [WATCH TIME: 3 minutes]
Reactions to FDA Advisory Panel Decision on AMX0035: Justin Klee; Josh Cohen, BSc
May 19th 2022The co-CEOs and co-founders of Amylyx Pharmaceuticals discussed their immediate thoughts to the recent FDA AdComm meeting, which voted against evidence of efficacy for AMX0035 in ALS. [WATCH TIME: 3 minutes]
Adding Experience to the National Health Institute Council: Amy Brin, MSN, MA, PCNS-BC
May 17th 2022The chief executive officer of the Child Neurology Foundation provided insight on her new position at the National Health Institute’s National Advisory Neurological Disorders and Stroke Council. [WATCH TIME: 4 minutes]